Aura Biosciences Inc (AURA) Price & Analysis

Compare

245 Followers

AURA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.35 - $12.38

Previous CloseN/A

Volume82.15K

Average Volume (3M)153.98K

Market Cap

$430.31M

Enterprise Value$203.98M

Total Cash (Recent Filing)$177.31M

Total Debt (Recent Filing)$18.11M

Price to Earnings (P/E)―

Beta2.17

Next Earnings

Nov 06, 2025

EPS Estimate

-0.46

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.47

Shares Outstanding62,004,322

10 Day Avg. Volume163,970

30 Day Avg. Volume153,976

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.47

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-679.93

Enterprise Value/Ebitda-2.65

Forecast

1Y Price Target

$21.80

Price Target Upside211.43% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyBel-sar has demonstrated tumor control in up to 80% of treated patients and 90% vision preservation at 12 months in choroidal melanoma.

Clinical TrialsThe initial data from bel-sar's trial in bladder cancer is promising.

Intellectual PropertyRecent IP developments, including a new formulation patent with potential exclusivity to 2046, further strengthen Aura’s competitive positioning.

Bears Say

Financial HealthThe company has an annualized cash burn of $100 million with approximately 1.8 years of cash remaining.

Investor SentimentThe short interest is 8.3% of the float, indicating a significant level of skepticism from some investors.

Regulatory ChallengesConcerns about the single arm design of the ENVISION trial, which the FDA views as insufficient to assess duration of response.

Aura Biosciences Inc News

Aura Biosciences reports Q2 EPS (47c) vs (41c) last year

“We continued to focus on execution in our clinical programs in the second quarter, including our ongoing global...

3d ago

AURA

Optimistic Buy Rating for Aura Biosciences Inc: Promising Pipeline, Strategic Positioning, and Strong Financials

Leerink Partners analyst Andrew Berens maintained a Buy rating on Aura Biosciences Inc on August 13 and set...

18h ago

AURA

Aura Biosciences Advances Clinical Trials and Strengthens Finances

Aura Biosciences Inc ( ($AURA) ) has released its Q2 earnings. Here is a breakdown of the information...

2d ago

AURA

Aura Biosciences Inc: Promising Clinical Developments and Strong Financial Position Support Buy Rating

TD Cowen analyst Phil Nadeau has maintained their bullish stance on AURA stock, giving a Buy rating today....

3d ago

AURA

Aura Biosciences Inc’s Promising Clinical Advancements and Strategic Positioning Justify Buy Rating

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Aura Biosciences Inc today and set a...

3d ago

AURA

Positive Outlook on Aura Biosciences: Strategic Developments and Promising Trials Drive Buy Rating

In a report released today, Oliver McCammon from LifeSci Capital maintained a Buy rating on Aura Biosciences Inc,...

3d ago

AURA

Aura Biosciences Reports Q2 Results and $75M Financing

Aura Biosciences Inc ( ($AURA) ) just unveiled an announcement. On August 13, 2025, Aura Biosciences reported its...

3d ago

AURA

3 ‘Strong Buy’ Russell 2000 Stocks with Triple-Digit Upside Potential

As the market continues to navigate economic uncertainty, investors are increasingly looking toward smaller companies with high growth...

1M ago

AURA

NUVB

Aura Biosciences Holds 2025 Annual Stockholders Meeting

The latest update is out from Aura Biosciences Inc ( ($AURA) ). On June 17, 2025, Aura Biosciences,...

2M ago

AURA

Innovative Precision Oncology and Promising Clinical Results Justify Buy Rating for Aura Biosciences Inc

Andres Y. Maldonado, an analyst from H.C. Wainwright, has initiated a new Buy rating on Aura Biosciences Inc...

3M ago

AURA

Aura Biosciences assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Andres Maldonado assumed coverage of Aura Biosciences (AURA) with a Buy rating and $22 price...

3M ago

AURA

Strategic Positioning and Regulatory Advantage Bolster Aura Biosciences Inc’s Buy Rating

Leerink Partners analyst Andrew Berens has maintained their bullish stance on AURA stock, giving a Buy rating on...

3M ago

AURA

Aura Biosciences 11.7M share Spot Secondary priced at $4.90

Leerink and Evercore ISI acted as joint book running managers for the offering. Published first on TheFly –...

3M ago

AURA

Aura Biosciences announces common stock, warrant offering, no amount given

Aura Biosciences (AURA) announced the launch of an underwritten public offering of shares of its common stock and...

3M ago

AURA

AURA FAQ

What was Aura Biosciences Inc’s price range in the past 12 months?

Aura Biosciences Inc lowest stock price was $4.34 and its highest was $12.38 in the past 12 months.

What is Aura Biosciences Inc’s market cap?

Aura Biosciences Inc’s market cap is $430.31M.

When is Aura Biosciences Inc’s upcoming earnings report date?

Aura Biosciences Inc’s upcoming earnings report date is Nov 06, 2025 which is in 82 days.

How were Aura Biosciences Inc’s earnings last quarter?

Aura Biosciences Inc released its earnings results on Aug 13, 2025. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.478 by $0.008.

Is Aura Biosciences Inc overvalued?

According to Wall Street analysts Aura Biosciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aura Biosciences Inc pay dividends?

Aura Biosciences Inc does not currently pay dividends.

What is Aura Biosciences Inc’s EPS estimate?

Aura Biosciences Inc’s EPS estimate is -0.46.

How many shares outstanding does Aura Biosciences Inc have?

Aura Biosciences Inc has 62,004,322 shares outstanding.

What happened to Aura Biosciences Inc’s price movement after its last earnings report?

Aura Biosciences Inc reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.478. Following the earnings report the stock price went up 4.179%.

Which hedge fund is a major shareholder of Aura Biosciences Inc?

Currently, no hedge funds are holding shares in AURA

Aura Biosciences Inc Stock Smart Score

Neutral

Fundamentals

Return on Equity

-55.39%

Trailing 12-Months

Asset Growth

-6.36%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aura Biosciences Inc

Aura Biosciences Inc (AURA) is a biotechnology company focused on developing novel therapies for the treatment of various cancers. The company's core product candidates are designed to selectively target and destroy cancer cells while minimizing damage to surrounding healthy tissues. Aura Biosciences is particularly known for its work in ocular oncology, including the development of proprietary virus-like drug conjugates that target ocular and other rare cancers.

Aura Biosciences Inc (AURA) Earnings & Revenues

Historic Earnings Reports

AURA Stock 12 Month Forecast

Average Price Target

$21.80

▲(211.43% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","14":"$14","19":"$19","24":"$24"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$23.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9,14,19,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.74,7.990769230769231,9.241538461538461,10.492307692307692,11.743076923076924,12.993846153846153,14.244615384615384,15.495384615384614,16.746153846153845,17.996923076923075,19.247692307692304,20.498461538461537,21.74923076923077,{"y":23,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.74,7.898461538461539,9.056923076923077,10.215384615384615,11.373846153846154,12.532307692307693,13.69076923076923,14.84923076923077,16.00769230769231,17.166153846153847,18.324615384615385,19.483076923076922,20.64153846153846,{"y":21.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.74,7.683076923076923,8.626153846153846,9.569230769230769,10.512307692307692,11.455384615384617,12.39846153846154,13.341538461538462,14.284615384615385,15.227692307692308,16.17076923076923,17.113846153846154,18.056923076923077,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.37,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.86,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.58,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.49,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.07,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.74,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >